Cargando…

TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway

Osteosarcoma is the most common type of bone cancer, and the second leading cause of cancer-related death in children and young adults. Osteosarcoma stem cells are essential for osteosarcoma initiation, metastasis, chemoresistance and recurrence. In the present study, we report that: 1) higher TSSC3...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Guang-Ning, Tang, Xue-Feng, Zhang, Xian-Chao, He, Ting, Huang, Yu-Sheng, Zhang, Xi, Meng, Gang, Guo, De-Yu, Lv, Yang-Fan, Guo, Qiao-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689636/
https://www.ncbi.nlm.nih.gov/pubmed/29156746
http://dx.doi.org/10.18632/oncotarget.20429
_version_ 1783279423054675968
author Yan, Guang-Ning
Tang, Xue-Feng
Zhang, Xian-Chao
He, Ting
Huang, Yu-Sheng
Zhang, Xi
Meng, Gang
Guo, De-Yu
Lv, Yang-Fan
Guo, Qiao-Nan
author_facet Yan, Guang-Ning
Tang, Xue-Feng
Zhang, Xian-Chao
He, Ting
Huang, Yu-Sheng
Zhang, Xi
Meng, Gang
Guo, De-Yu
Lv, Yang-Fan
Guo, Qiao-Nan
author_sort Yan, Guang-Ning
collection PubMed
description Osteosarcoma is the most common type of bone cancer, and the second leading cause of cancer-related death in children and young adults. Osteosarcoma stem cells are essential for osteosarcoma initiation, metastasis, chemoresistance and recurrence. In the present study, we report that: 1) higher TSSC3 expression indicates a better prognosis for osteosarcoma patients, and; 2) overexpression of TSSC3 significantly decreases sphere-forming capacity, tumor initiation, stemness-related surface markers and Nanog expression in osteosarcoma cells. We also discovered that higher Nanog expression correlates to a worse prognosis for osteosarcoma patients, and overexpression of Nanog increases the stem-related phenotype in osteosarcoma cells. Knockdown of Nanog suppresses these phenotypes. Inhibition of Nanog expression and self-renewal of osteosarcoma cells by TSSC3 overexpression appears to be mediated through inactivation of the Src/Akt pathway. In the clinical setting, expression of TSSC3, p-Src and Nanog is associated with recurrence, metastasis and surgical intervention. Lower TSSC3 expression, higher Nanog expression or higher p-Src expression indicate a poor prognosis for osteosarcoma patients. Overall, our study demonstrates that TSSC3 inhibits the stem-like phenotype and Nanog expression by inactivation of the Src/Akt pathway; this emphasizes the importance of Nanog in osteosarcoma stem cells.
format Online
Article
Text
id pubmed-5689636
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56896362017-11-17 TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway Yan, Guang-Ning Tang, Xue-Feng Zhang, Xian-Chao He, Ting Huang, Yu-Sheng Zhang, Xi Meng, Gang Guo, De-Yu Lv, Yang-Fan Guo, Qiao-Nan Oncotarget Research Paper Osteosarcoma is the most common type of bone cancer, and the second leading cause of cancer-related death in children and young adults. Osteosarcoma stem cells are essential for osteosarcoma initiation, metastasis, chemoresistance and recurrence. In the present study, we report that: 1) higher TSSC3 expression indicates a better prognosis for osteosarcoma patients, and; 2) overexpression of TSSC3 significantly decreases sphere-forming capacity, tumor initiation, stemness-related surface markers and Nanog expression in osteosarcoma cells. We also discovered that higher Nanog expression correlates to a worse prognosis for osteosarcoma patients, and overexpression of Nanog increases the stem-related phenotype in osteosarcoma cells. Knockdown of Nanog suppresses these phenotypes. Inhibition of Nanog expression and self-renewal of osteosarcoma cells by TSSC3 overexpression appears to be mediated through inactivation of the Src/Akt pathway. In the clinical setting, expression of TSSC3, p-Src and Nanog is associated with recurrence, metastasis and surgical intervention. Lower TSSC3 expression, higher Nanog expression or higher p-Src expression indicate a poor prognosis for osteosarcoma patients. Overall, our study demonstrates that TSSC3 inhibits the stem-like phenotype and Nanog expression by inactivation of the Src/Akt pathway; this emphasizes the importance of Nanog in osteosarcoma stem cells. Impact Journals LLC 2017-08-24 /pmc/articles/PMC5689636/ /pubmed/29156746 http://dx.doi.org/10.18632/oncotarget.20429 Text en Copyright: © 2017 Yan et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Yan, Guang-Ning
Tang, Xue-Feng
Zhang, Xian-Chao
He, Ting
Huang, Yu-Sheng
Zhang, Xi
Meng, Gang
Guo, De-Yu
Lv, Yang-Fan
Guo, Qiao-Nan
TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway
title TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway
title_full TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway
title_fullStr TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway
title_full_unstemmed TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway
title_short TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway
title_sort tssc3 represses self-renewal of osteosarcoma stem cells and nanog expression by inhibiting the src/akt pathway
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689636/
https://www.ncbi.nlm.nih.gov/pubmed/29156746
http://dx.doi.org/10.18632/oncotarget.20429
work_keys_str_mv AT yanguangning tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway
AT tangxuefeng tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway
AT zhangxianchao tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway
AT heting tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway
AT huangyusheng tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway
AT zhangxi tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway
AT menggang tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway
AT guodeyu tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway
AT lvyangfan tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway
AT guoqiaonan tssc3repressesselfrenewalofosteosarcomastemcellsandnanogexpressionbyinhibitingthesrcaktpathway